Why Is SPYRE THERAPEUTICS I (SYRE) Stock Down Today?

Spyre Therapeutics (SYRE) fell 13.63% to $92.72 on Tuesday, marking a sharp reversal from its recent upward trend. The decline followed the company's announcement that it will halt development of its rheumatoid arthritis drug candidate, SPY072, after mixed results from a Phase 2 trial. The decision spooked investors, triggering a steep intraday drop and a gap down from the prior close.

What Happened

The stock opened at $94.53, down 11.9% from the previous day's close of $107.36, and quickly fell to a session low of $90.60. The move came as Spyre Therapeutics disclosed it would no longer pursue SPY072 for rheumatoid arthritis, a key development in its pipeline. This decision followed what the company described as "disappointing" Phase 2 data, which raised questions about the drug's efficacy. The stock continued to trade lower throughout the session, closing at $93.00.

Multiple analysts adjusted their price targets in response to the news. Wedbush cut its target to $123 from $130, BTIG lowered it to $121 from $132, and Deutsche Bank reduced its estimate to $127 from $135. While all three firms maintained positive outlooks, the downward revisions reflected reduced optimism about the stock's near-term potential.

What The Data Shows

Spyre Therapeutics has a market cap of $9.4 billion and has been unprofitable, with a trailing twelve-month earnings per share of -2.01 and a 100% year-over-year revenue decline. The stock has a beta of 3.03, indicating high volatility. Over the past eight sessions, it had risen 4.8% from $102.32 to $107.22. However, the recent drop pushed it closer to its 52-week low of $14.51, with the stock printing two fresh 52-week lows on August 26.

Insider activity has also been bearish, with 12 sales filings totaling $412.4 million in the last 90 days. The most recent insider sales occurred on August 10, with CEO Cameron Turtle and CFO Scott Burrows among those who sold shares.

What To Watch

Spyre Therapeutics has no upcoming earnings date scheduled. Investors will want to monitor the breadth of analyst coverage and any further updates on the company's remaining pipeline milestones for the remainder of 2026.